Boehringer Ingelheim (Canada) Ltd.

Boehringer Ingelheim International Gmbh

Gilead Sciences, Inc.

Boehringer Ingelheim Gmbh

Bio-mega/boehringer Ingelheim Research Inc.

Marc-Andre Poupart

Murray D Bailey

Teddy Halmos

Jean Rancourt

Youla S Tsantrizos

Montse Llinas-Brunet

Nathalie Goudreau

Elise Ghiro

Dale R Cameron

Anne-Marie Faucher

Dominik M Wernic

Pierre Louis Beaulieu

Bruno Simoneau

Gulrez Fazal

Stephen Kawai

James Gillard

George Kukolj

Lee Fader

Mathieu Parisien

Serge R Landry

Sebastien Morin

Francois Bilodeau

Rebekah J Carson

Eric Jolicoeur

Rene Coulombe

Steven LaPlante

Martin Poirier

Christian Brochu

Paul John Edwards

Sylvie Goulet

Pierre Lavallee

Paul C Anderson

Pasquale Forgione

Punit R Bhardwaj

Catherine Chabot

Grace L Jung

Araz Jakalian

Ellse Ghiro

Punit-Kumar Bhardwaj

William Ogilvie

Compounds of formula I: wherein R, Rand Rare defined herein, are useful as inhibitors of HIV replication.

Inhibitors of human immunodeficiency virus replication

Compounds of formula (I): wherein c, X, Y, R, Rand Rare defined herein, are useful as inhibitors of HIV replication. 

Racemates, diastereoisomers and optical isomers of a compound of formula (I):wherein

Hepatitis C inhibitor tri-peptides

An isomer, enantiomer, diastereoisomer, or tautomer of a compound, represented by formula I: wherein:

Viral polymerase inhibitors

Compounds of formula (I):  wherein R, R, R, R, n and m are as defined herein. The compounds are useful as inhibitors of HCV NS3 protease.

Hepatitis C inhibitor dipeptide analogs

Racemates, diastereolsomers and optical isomers of a compound of formula (I):wherein B is H, a Cor Caryl, Caralkyl; Het or (lower alkyl)-Het, all of which optionally substituted with Calkyl; Calkoxy; Calkanoyl; hydroxy; hydroxyalkyl; halo; haloalkyl; nitro; cyano; cyanoalkyl; amino optionally substituted with Calkyl; amido; or (lower alkyl)amide; or

The invention relates to compounds of formula (I) wherein R', R, R, R, R, R, Y, n and m are as defined herein. The compounds are useful for the treatment and prevention of hepatitis C viral infections in mammals by inhibiting HCV NS3 protease. The invention further relates to azalactone compounds of the formula (III) which can be reacted with an amide anion to produce the compounds of formula (I). 

Hepatitis C inhibitor peptide analogs

An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein: wherein Rand Rand Q are as defined herein;

An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein wherein A, B, R, R, L, M, M, M, M, Y, Y, Z and Sp are as defined in claim, or a salt thereof, as an inhibitor of HCV NS5B polymerase.

An isomer, enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein A, B, R, R, M, M, M, M, Yand Z are as defined in claim 1, or a salt thereof, as an inhibitor of HCV NS5B polymerase 

Growing community of inventors

Laval, Canada

Marc-Andre Poupart